TY - JOUR
T1 - Diagnosis and treatment of hyperprolactinemia
T2 - An endocrine society clinical practice guideline
AU - Melmed, Shlomo
AU - Casanueva, Felipe F.
AU - Hoffman, Andrew R.
AU - Kleinberg, David L.
AU - Montori, Victor M.
AU - Schlechte, Janet A.
AU - Wass, John A.H.
PY - 2011/2
Y1 - 2011/2
N2 - Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. Conclusions: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
AB - Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. Conclusions: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
UR - http://www.scopus.com/inward/record.url?scp=79951685894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951685894&partnerID=8YFLogxK
U2 - 10.1210/jc.2010-1692
DO - 10.1210/jc.2010-1692
M3 - Review article
C2 - 21296991
AN - SCOPUS:79951685894
SN - 0021-972X
VL - 96
SP - 273
EP - 288
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 2
ER -